FIELD: pharmacology, in particular agent for treatment and/or prophylaxis of Parkinson disease or Parkinson syndrome.
SUBSTANCE: claimed agent includes compound improving astrocyte function as active ingredient, namely (R)-2-propyloctanoic acid, non-toxic salt or hydrate thereof. Method for production of claimed agent by using (R)-2-propyloctanoic acid also is disclosed.
EFFECT: agent for high effective treatment.
3 cl, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATIONS CONTAINING mGluR MODULATORS FOR TREATING PARKINSON'S DISEASE | 2009 |
|
RU2496494C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PARKINSON'S DISEASE AND PARKINSON'S SYNDROME, METHOD FOR ITS PREPARING, METHOD FOR TREATMENT OF PARKINSON'S DISEASE AND PARKINSON'S SYNDROME | 1994 |
|
RU2221563C2 |
| RASAGILINE COMPOSITIONS WITH PROLONGED RELEASE AND USE THEREOF | 2011 |
|
RU2734632C2 |
| RASAGILINE COMPOSITIONS OF PROLONGED RELEASE AND USE THEREOF | 2011 |
|
RU2607595C2 |
| IMIDAZODIAZEPINE COMPOUND | 2016 |
|
RU2712968C2 |
| IMIDAZODIAZEPINE COMPOUND | 2016 |
|
RU2777915C2 |
| GSK-3 INHIBITORS | 2006 |
|
RU2449998C2 |
| METABOTROPIC GLUTAMATE RECEPTOR MODULATORS FOR TREATING PARKINSON'S DISEASE | 2008 |
|
RU2508107C2 |
| NOVEL USING 2-[5-(4-FLUOROPHENYL)-3-PYRIDYLMETHYLAMINOMETHYL]-CHROMAN AND ITS PHYSIOLOGICALLY ACCEPTABLE SALTS | 2002 |
|
RU2297833C2 |
| PHARMACEUTICAL COMPOSITION FOR INHIBITING NEURONAL APOPTOSIS OR NEURODEGENERATION | 2011 |
|
RU2586772C2 |
